Your browser doesn't support javascript.
loading
Pre-treatment levels of inflammatory markers and chemotherapy completion rates in patients with early-stage breast cancer.
Schauer, Tim; Henriksson, Anna; Strandberg, Emelie; Lindman, Henrik; Berntsen, Sveinung; Demmelmaier, Ingrid; Raastad, Truls; Nordin, Karin; Christensen, Jesper F.
Afiliación
  • Schauer T; Centre for Physical Activity Research, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark. tim.schauer.01@regionh.dk.
  • Henriksson A; Department of Public Health and Caring Sciences, Uppsala University, Husargatan 3, 751 22, Uppsala, Sweden.
  • Strandberg E; Department of Public Health and Caring Sciences, Uppsala University, Husargatan 3, 751 22, Uppsala, Sweden.
  • Lindman H; Department of Oncology, Uppsala University, 751 85, Sjukhusvägen, Uppsala, Sweden.
  • Berntsen S; Department of Public Health and Caring Sciences, Uppsala University, Husargatan 3, 751 22, Uppsala, Sweden.
  • Demmelmaier I; Department of Sport Science and Physical Education, University of Agder, Universitetsveien 25, 4630, Kristiansand, Norway.
  • Raastad T; Department of Public Health and Caring Sciences, Uppsala University, Husargatan 3, 751 22, Uppsala, Sweden.
  • Nordin K; Department of Sport Science and Physical Education, University of Agder, Universitetsveien 25, 4630, Kristiansand, Norway.
  • Christensen JF; Department of Sport Science and Physical Education, University of Agder, Universitetsveien 25, 4630, Kristiansand, Norway.
Int J Clin Oncol ; 28(1): 89-98, 2023 Jan.
Article en En | MEDLINE | ID: mdl-36269530
ABSTRACT

BACKGROUND:

Chemotherapy efficacy is largely dependent on treatment adherence, defined by the relative dose intensity (RDI). Identification of new modifiable risk factors associated with low RDI might improve chemotherapy delivery. Here, we evaluated the association between low RDI and pre-chemotherapy factors, including patient- and treatment-related characteristics and markers of inflammation.

METHODS:

This exploratory analysis assessed data from 267 patients with early-stage breast cancer scheduled to undergo (neo-)adjuvant chemotherapy included in the Physical training and Cancer (Phys-Can) trial. The association between low RDI, defined as < 85%, patient-related (age, body mass index, co-morbid condition, body surface area) and treatment-related factors (cancer stage, receptor status, chemotherapy duration, chemotherapy dose, granulocyte colony-stimulating factor) was investigated. Analyses further included the association between RDI and pre-chemotherapy levels of interleukin (IL)-6, IL-8, IL-10, C-reactive protein (CRP) and Tumor Necrosis Factor-alpha (TNF-α) in 172 patients with available blood samples.

RESULTS:

An RDI of < 85% occurred in 31 patients (12%). Univariable analysis revealed a significant association with a chemotherapy duration above 20 weeks (p < 0.001), chemotherapy dose (p = 0.006), pre-chemotherapy IL-8 (OR 1.61; 95% CI (1.01; 2.58); p = 0.040) and TNF-α (OR 2.2 (1.17; 4.53); p = 0.019). In multivariable analyses, inflammatory cytokines were significant association with low RDI for IL-8 (OR 1.65 [0.99; 2.69]; p = 0.044) and TNF-α (OR 2.95 [1.41; 7.19]; p = 0.007).

CONCLUSIONS:

This exploratory analysis highlights the association of pre-chemotherapy IL-8 and TNF-α with low RDI of chemotherapy for breast cancer. IL-8 and TNF-α may therefore potentially help to identify patients at risk for experiencing dose reductions. Clinical trial number NCT02473003 (registration June 16, 2015).
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Int J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Dinamarca

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Int J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Dinamarca